Fig. 1From: Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistanceBRAF V600E. This figure schematically depicts the main linear alternative splicing events of BRAF V600E. The RAS-binding domain is missing by skipping exon 4–8, which induces the resistance to vemurafenibBack to article page